Shama Parween

Shama Parween

Auto-generated profile, based on publicly available information

Shama Parween

CellSight Ocular Stem Cell and Regeneration Research Program, Sue Anschutz-Rodgers Eye Center, University of Colorado School of Medicine, Aurora, CO, USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 March 2025 in Communications Medicine
Verified
Journal Article
Open access
PDF file
ABAlexandra Bernardo-Colón
Alexandra Bernardo-Colón
ABAndrea Bighinati
Andrea Bighinati
SPShama Parween
Shama Parween
SDSubrata Debnath
Subrata Debnath
Ilaria PianoIlaria Piano
Ilaria Piano
SBS. Patricia Becerra
S. Patricia Becerra
Background: Photoreceptor death leads to inherited blinding retinal diseases, such as retinitis pigmentosa (RP). As disease progression often outpaces therapeutic advances, developing effective treatments is urgent. This study evaluates the efficacy of small peptides derived from pigment epithelium-derived factor (PEDF), which are known to restrict common cell death pathways associated with retinal diseases. Methods: We tested chemically synthesized peptides (17-mer and H105A) with affinity for the PEDF receptor, PEDF-R, delivered as eye drops to two RP mouse models: rd10 (phosphodiesterase 6b mutation) and Rho P23H/+ (rhodopsin P23H mutation). Additionally, we engineered AAV-H105A vectors for intravitreal delivery in Rho P23H/+ mice. To assess peptide effects in human tissue, we used retinal organoids exposed to cigarette smoke extract, a model of oxidative stress. Photoreceptor survival, morphology and function were evaluated. Results: Here we show that peptides 17-mer and H105A delivered via eye drops successfully reach the retina, promote photoreceptor survival, and improve retinal function in both RP mouse models. Intravitreal delivery of a AAV-H105A vector delays photoreceptor degeneration in Rho P23H/+ mice up to six months. In human retinal organoids, peptide H105A specifically prevents photoreceptor death induced by oxidative stress, a contributing factor to RP progression. Conclusions: PEDF peptide-based eye drops offer a promising, minimally invasive therapy to prevent photoreceptor degeneration in retinal disorders, with a favorable safety profile.

20 November 2025 in Drug Discovery Today
Verified
Journal Article
Closed access
RSRafael A Silva
Rafael A Silva
AHAnna Howell
Anna Howell
KJKendra Jones-Graham
Kendra Jones-Graham
SPShama Parween
Shama Parween
Ana Paula GirolAna Paula Girol
Ana Paula Girol
MVM. Natalia Vergara
M. Natalia Vergara

16 July 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
ABAlexandra Bernardo-Colón
Alexandra Bernardo-Colón
ABAndrea Bighinati
Andrea Bighinati
SPShama Parween
Shama Parween
SDSubrata Debnath
Subrata Debnath
Ilaria PianoIlaria Piano
Ilaria Piano
SBS. Patricia Becerra
S. Patricia Becerra
Photoreceptor death causes blinding inheritable retinal diseases, such as retinitis pigmentosa (RP). As disease progression often outpaces therapeutic advances, finding effective treatments is urgent. This study focuses on developing a targeted approach by evaluating the efficacy of small peptides derived from pigment epithelium-derived factor (PEDF), known to restrict common cell death pathways associated with retinal diseases. Peptides with affinity for the PEDF receptor, PEDF-R, (17-mer and H105A) delivered via eye drops reached the retina, efficiently promoted photoreceptor survival, and improved retinal function in RP mouse models based on both the rd10 mutation and the rhodopsin P23H mutation. Additionally, intravitreal delivery of AAV-H105A vectors delayed photoreceptor degeneration in the latter RP mouse model. Furthermore, peptide H105A specifically prevented photoreceptor death induced by oxidative stress, a contributing factor to RP progression, in human retinal organoids. This promising approach for peptide eye drop delivery holds significant potential as a therapeutic for preventing photoreceptor death in retinal disorders, offering a high safety profile, low invasiveness and multiple delivery options. One Sentence Summary: Neurotrophic PEDF peptides delivered as eye drops preserve photoreceptor viability, morphology, and function in models of human retinal diseases.

22 August 2026 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
RSRafael A Silva
Rafael A Silva
SPShama Parween
Shama Parween
AHAnna Howell
Anna Howell
SHSydney Hayden
Sydney Hayden
PRPaul A. Roberson
Paul A. Roberson
MVM. Natalia Vergara
M. Natalia Vergara